Evidence map›Paper›PMID 32750010›Full record

ArticleJournal of medical Internet research2020

Managing COVID-19 With a Clinical Decision Support Tool in a Community Health Network: Algorithm Development and Validation.

Michael P McRae, Isaac P Dapkins, Iman Sharif, Judd Anderman, David Fenyo, Odai Sinokrot, Stella K Kang, Nicolaos J Christodoulides, Deniz Vurmaz, Glennon W Simmons and 5 more

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Managing Pandemics with Health Informatics.Yearbook of medical informatics · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael P McRaeDepartment of Biomaterials, Bioengineering Institute, New York University College of Dentistry, New York, NY, United States.ORCID 0000-0002-2126-9442
Isaac P DapkinsDepartment of Population Health and Internal Medicine, Family Health Centers at NYU Langone, New York University School of Medicine, New York, NY, United States.ORCID 0000-0001-5257-8064
Iman SharifDepartments of Pediatrics and Population Health, Family Health Centers at NYU Langone, New York University School of Medicine, New York, NY, United States.ORCID 0000-0002-8641-4938
Judd AndermanFamily Health Centers at NYU Langone, New York, NY, United States.ORCID 0000-0003-0682-9445
David FenyoDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, United States.ORCID 0000-0001-5049-3825
Odai SinokrotDepartment of Medicine, New York University School of Medicine, New York, NY, United States.ORCID 0000-0003-1846-2687
Stella K KangDepartment of Radiology, New York University School of Medicine, New York, NY, United States.ORCID 0000-0003-2402-3787
Nicolaos J ChristodoulidesDepartment of Biomaterials, Bioengineering Institute, New York University College of Dentistry, New York, NY, United States.ORCID 0000-0002-6494-5586
Deniz VurmazDepartment of Chemical and Biomolecular Engineering, NYU Tandon School of Engineering, New York University, New York, NY, United States.ORCID 0000-0002-0591-6371
Glennon W SimmonsDepartment of Biomaterials, Bioengineering Institute, New York University College of Dentistry, New York, NY, United States.ORCID 0000-0003-4560-2809
Timothy M AlcornLatham BioPharm Group, Cambridge, MA, United States.ORCID 0000-0001-5255-4302
Marco J DaouraOraLiva, Naples, FL, United States.ORCID 0000-0003-2475-2592
Stu GisburneOraLiva, Naples, FL, United States.ORCID 0000-0002-2981-6439
David ZarOraLiva, Naples, FL, United States.ORCID 0000-0002-2853-0076
John T McDevittDepartment of Biomaterials, Bioengineering Institute, New York University College of Dentistry, New York, NY, United States.ORCID 0000-0001-8789-9351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coronavirus disease (COVID-19) pandemic has resulted in significant morbidity and mortality; large numbers of patients require intensive care, which is placing strain on health care systems worldwide. There is an urgent need for a COVID-19 disease severity assessment that can assist in patient triage and resource allocation for patients at risk for severe disease.

objectiveThe goal of this study was to develop, validate, and scale a clinical decision support system and mobile app to assist in COVID-19 severity assessment, management, and care.

methodsModel training data from 701 patients with COVID-19 were collected across practices within the Family Health Centers network at New York University Langone Health. A two-tiered model was developed. Tier 1 uses easily available, nonlaboratory data to help determine whether biomarker-based testing and/or hospitalization is necessary. Tier 2 predicts the probability of mortality using biomarker measurements (C-reactive protein, procalcitonin, D-dimer) and age. Both the Tier 1 and Tier 2 models were validated using two external datasets from hospitals in Wuhan, China, comprising 160 and 375 patients, respectively.

resultsAll biomarkers were measured at significantly higher levels in patients who died vs those who were not hospitalized or discharged (P<.001). The Tier 1 and Tier 2 internal validations had areas under the curve (AUCs) of 0.79 (95% CI 0.74-0.84) and 0.95 (95% CI 0.92-0.98), respectively. The Tier 1 and Tier 2 external validations had AUCs of 0.79 (95% CI 0.74-0.84) and 0.97 (95% CI 0.95-0.99), respectively.

conclusionsOur results demonstrate the validity of the clinical decision support system and mobile app, which are now ready to assist health care providers in making evidence-based decisions when managing COVID-19 patient care. The deployment of these new capabilities has potential for immediate impact in community clinics and sites, where application of these tools could lead to improvements in patient outcomes and cost containment.

Indexed as

BetacoronavirusCommunity NetworksCoronavirusCoronavirus InfectionsCOVID-19Decision Support Systems, ClinicalFemaleHumansMalePandemicsPneumonia, ViralSARS-CoV-2appartificial intelligencebiomarkersclinical decision support systemcoronavirusCOVID-19disease severityfamily health centermobile apppoint of care

Identifiers

PMID32750010
PMCPMC7446714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.